Key facts
- Accelus’s last known valuation is $342.0M (Jul 2022).
- It has raised $68.2M; the latest was Buyout/LBO in Aug 2025.
- Notable investors include Kinled Holding, Eastward Capital Partners, Trog Hawley Capital, Concord Health Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Accelus
- ·The full record, as it builds
Funding rounds
No funding rounds for Accelus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accelus
Developer of medical implants designed to focus on expandable interbody technology for spine surgery. The company's implants are a bi-directional expandable cage with the strength and rigidity of a monolithic implant, enabling doctors and orthopedic surgeons to treat height, weight, or lordosis problems.
- Sector
- Healthcare
- HQ
- Palm Beach Gardens, FL, United States
- Founded
- 2016
- Employees
- 68
- Website
- accelusinc.com/
- Ownership
- Privately Held (backing)
Accelus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accelus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accelus in its N-PORT filings yet. We sweep new filings monthly.